Medicare to Cover Weight Loss Drugs at $50 Copay Starting July
Millions of Medicare beneficiaries will soon have access to popular weight loss medications including Wegovy and Zepbound at a significantly reduced $50 copay, making these GLP-1 drugs more affordable for older Americans starting in July.
Expanded Medicare Coverage
Weight management medications, including Wegovy, Zepbound and Foundayo, will be available to eligible Medicare beneficiaries with a $50 copay starting in July. Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss.
Impact on Healthcare Access
This policy expansion represents a significant step in making advanced weight management treatments more accessible to senior populations, reducing financial barriers to prescription medications that have shown effectiveness in weight management and metabolic health.